In:
Journal of Geriatric Psychiatry and Neurology, SAGE Publications, Vol. 13, No. 1 ( 2000-04), p. 43-48
Abstract:
The authors present data from an open trial of fluvoxamine (median daily dosage: 200 mg) in the treatment of generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder in 19 older outpatients (mean age = 66.8). Of the 12 subjects completing the 21-week trial, 8 achieved a good response (50% reduction in symptom measures) and 7 were rated as much or very much improved. Fluvoxamine pharmacotherapy also had a significant effect in reducing comorbid depressive symptoms and in increasing levels of functioning. These data support the effectiveness of fluvoxamine in older subjects with anxiety disorders (particularly generalized anxiety disorder) and warrant further double-blind, placebo-controlled evaluation. ( J Geriatr Psychiatry Neurol 2000; 13:43—48).
Type of Medium:
Online Resource
ISSN:
0891-9887
,
1552-5708
DOI:
10.1177/089198870001300107
Language:
English
Publisher:
SAGE Publications
Publication Date:
2000
detail.hit.zdb_id:
2094096-8